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No data are available regarding the management of cancer patients requiring interruption of long-term vita-
min-K antagonist (VKA) therapy. For this purpose, we tested the efﬁcacy and safety of ﬁxed doses of low-
molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-
induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery
or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at ﬁxed subthera-
peutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated
12 hr after surgery and VKA the day after. In patients receiving chemotherapy, LMWH was reinitiated 12/24
hr after obtaining a stable platelet count  30,000 mmc3 and VKA after a stable platelet count  50,000
mmc3. Thromboembolism and major bleeding events were recorded from the time of VKA suspension to 30
± 2 days postprocedure or until the next chemotherapy. Overall, 156 patients (56.4% at low risk and 43.5%
at high risk for thrombosis) were enrolled; 34.6% underwent major surgery, 40.4% nonmajor surgery, and
25% chemotherapy. Thrombotic events occurred in ﬁve patients [3.2%, 95% conﬁdence interval (CI): 1.41–
7.27], four belonging to the high-risk and one to the low-risk group. Major bleeding occurred in ﬁve patients
(3.2%, 95 CI: 1.41–7.27), all belonging to the high-risk group (three during major surgery and two during
chemotherapy). In conclusion, LMWH given at ﬁxed subtherapeutic is a feasible and relatively safe
approach for bridging therapy in cancer patients on long-term VKA. Am. J. Hematol. 87:388–391,
2012. VC 2012 Wiley Periodicals, Inc.
Introduction
Cancer patients receiving long-term vitamin-K antagonist
(VKA) therapy pose a clinical challenge when anticoagulant
therapy needs to be interrupted for surgical/invasive proce-
dures or chemotherapy-induced thrombocytopenia [1].
Interruption of anticoagulant therapy exposes patients to an
increased risk of thromboembolic events (TE) (i.e., stroke
or mechanical valve thrombosis), although such a risk
varies depending on the indication for the antithrombotic
therapy and on the presence of comorbid conditions [2].
Conversely, the administration of anticoagulants during sur-
gical procedures increases the risk of major bleeding. To
manage such situations, two options are available. The ﬁrst
strategy is to continue oral anticoagulation therapy with a
temporary adjustment of warfarin intensity to a preoperative
international normalized ratio (INR) of 1.5–2.0. However,
such an approach is associated with a high rate of bleeding
in noncancer patients [3]. Another strategy involves switch-
ing VKA to low-molecular weight heparin (LMWH; so-called
bridging therapy) some days before the procedure, at
doses and timings related to the individual thrombotic bur-
den as well as their bleeding risk due to the procedure.
This last approach has been proven to reduce the throm-
botic risk without increasing the occurrence of periproce-
dural major bleeding [4–8]. However, in none of the pro-
spective studies evaluating the safety of ‘‘bridging therapy’’
it is possible to extrapolate data on the cancer population.
Cancer patients are a high-risk population both for throm-
bosis and bleeding [9]; moreover, cancer-related therapy
may decrease platelet count, thus increasing the risk for
periprocedural bleeding [10–12]. Therefore, the use of anti-
coagulation in such a population may be difﬁcult and
requires appropriate investigation.
For this purpose, we prospectively tested the use of ﬁxed
subtherapeutic doses of LMWH as a bridging therapy in
cancer patients on long-term VKA requiring the suspension
of anticoagulation because of an expected high risk of
bleeding during surgery or other invasive procedures or
from chemotherapy-induced thrombocytopenia.
Materials and Methods
Patient population. This was a prospective, cohort study evaluating
the feasibility and safety of subcutaneous LMWH, administered primar-
ily at home, in cancer patients on long-term VKA therapy for whom
bridging therapy with heparin was planned because of exposure to pro-
cedures carrying the potential risk of bleeding. The study was con-
ducted between 2005 and 2010 at the University Hospital of Palermo,
Italy. The primary aim was to determine the incidence of periprocedural
thromboembolic events and major bleeding during the administration of
bridging anticoagulation over the 30 days following surgery.
Inclusion criteria included consecutive adult cancer patients requiring
long-term VKA therapy for mechanical heart valves, patients with atrial
ﬁbrillation (AF), stroke with an embolic source, venous thromboembo-
lism (VTE), or other indications (Table I) planned for any procedure
requiring the interruption of VKA (as listed above) or chemotherapy-
induced thrombocytopenia. Patients were excluded for the following
reasons: plans to undergo minor surgery or a simple dental procedure,
renal insufﬁciency (serum creatinine > 2.0 mg/dL), previous major
bleeding episode (i.e., haemorrhagic stroke), chronic anaemia (haemo-
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globin  10 g/L), or persistently low-platelet count (<100,000 per mm3)
not related to chemotherapy, severe associated pathologies (i.e.,
uncontrolled hypertension or diabetes and severe hepatic failure), preg-
nancy, anticoagulant therapy other than warfarin or acenocoumarol, or
when body weight  40 kg or  100 kg. Patients with known sensitiv-
ities to pork products, murine proteins, UFH, or LMWH or any of its
constituents, or a history of heparin-induced thrombocytopenia were
also excluded. Procedures were categorized as major (any operation
with an expected duration  1 hr), nonmajor surgery (invasive proce-
dures lasting  1 hr, such as gastro- or colonoscopy requiring biopsy),
or chemotherapy-induced thrombocytopenia.
Study Design
The periprocedural management of anticoagulation is
outlined in Fig. 1. Patients were categorized as being at a
low or high risk of thrombosis. The ﬁrst group included
patients suffering with AF with no previous arterial throm-
boembolism (TE; AF-noAT), VTE lasting more than 3
months, those with prosthetic aortic valves, or another indi-
cation (Table I). The high-risk group included patients with
AF with previous arterial TE (AF-AT), prosthetic mitral
valves, or those with recent VTE (lasting  3 months).
Preprocedural management
In all patients, VKA was discontinued 5 ± 1 days before
the procedure. In patients considered to be at a low risk of
thrombosis (low-risk group), LMWH was initiated once daily
at a prophylactic dosage (3,800 or 4,000 U.I. anti-FXa
according to the use of nadroparin or enoxaparin, respec-
tively), the night before the procedure. In patients consid-
ered to be at a high risk of thrombosis (high-risk group),
the INR was checked daily preoperatively; when an INR
value  1.5 was obtained, LMWH was initiated twice daily
at a ﬁxed subtherapeutic dose (3,800 or 4,000 U.I. anti-FXa
according to the use of nadroparin or enoxaparin, respec-
tively) and continued until the night before the procedure.
Postprocedural management
Twelve hours after the procedure, LMWH was given at a
prophylactic dose in the low-risk group and at a ﬁxed sub-
therapeutic dose in the high-risk group (as reported above).
VKA was restarted the day after the procedure or later in
the case of inadequate haemostasis; the dose of warfarin
was the same as the patient’s usual daily dose. Heparin was
continued until the INR value fell within a therapeutic range.
The physician had the option of delaying the ﬁrst postproce-
dural LMWH in cases where there was an increased risk of
bleeding. Hemoglobin and platelet levels were measured ev-
ery 1–2 days while patients were on LMWH. The INR was
measured every 1–2 days during the ﬁrst week after the pro-
cedure. The follow-up period extended from the day of the
procedure to about 1 month (30 ± 2 days) thereafter.
In patients who experienced chemotherapy-induced throm-
bocytopenia, VKA was discontinued 5 ± 1 days before chem-
otherapy, and LMWH therapy was commenced the day after
(following the same scheme reported above, according to the
risk-group). Heparin was discontinued when the platelet
count dropped to less than 30,000 mmc3; LMWH was reiniti-
ated 12–24 hr after a stable platelet count  30,000 mmc3
was reached, and VKA was reinitiated 12–24 h after reaching
a stable platelet count  50,000 mmc3. Heparin was contin-
ued until the INR value fell within a therapeutic range.
Patients were screened within 30 ± 2 days following the
procedure or chemotherapy for any potential signs or symp-
toms suggestive of thrombosis and/or bleeding or any other
serious medical condition.
Statistics and Ethics
The intention-to-treat (ITT) study population was deﬁned
as all patients who received at least one dose of LMWH. All
analyses were performed on this population. Baseline patient
characteristics and the periprocedural anticoagulation regi-
men were expressed as mean values with corresponding
standard deviations. Clinical outcome rates (recurrent TE,
TABLE I. Baseline Characteristics
Patients characteristics (n 5 156)
Mean age (range, years) 66.6 (32/89)
M/F (%) 84/72
Weight, mean ± SD (kg) 75.4 ± 16.5
Solid cancer, n (%) 98 (62.8)
Haematological cancer, n (%) 58 (37.2)
Advanced/metastatic cancer, n (%) 101 (64.7)
Bridging therapy with nadroparin, n (%) 71 (45.5)
Bridging therapy with enoxaparin, n (%) 79 (50.6)
Bridging therapy with others heparin compounds, n (%) 6 (3.8)
Low-risk for TE 88 (56.4)
Patients on chemotherapy-induced thrombocytopenia 22a
High-risk for TE 68 (43.5)
Patients on chemotherapy-induced thrombocytopenia 17b
Venous thromboembolism, n (%) 52 (33.3)
Events lasting < 3 months, n (%) 28
Events lasting > 3 months, n (%) 24
Atrial ﬁbrillation without previous stroke (AF-NoAT), n (%) 48 (30.7)
Atrial ﬁbrillation with previous stroke (AF-AT), n (%) 21 (13.4)
Prosthetic aortic/mitral valves, n (%) 19 (12.1)
Others (arterial hypertension, dilatative
myocardiopathy, valvulopathy, myocardial
infarction, coronary artery by-pass graft), n (%)
16 (10.2)
a
16 (72.7%) had haematological malignancies.
b
11 (64.7%) had haematological malignancies.
Figure 1. Study protocol.
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bleeding, and death) were expressed as a proportion with a
corresponding upper 95% conﬁdence interval (CI). Fre-
quency analysis was performed using the Fisher’s exact test
suitable for small samples. Based on the incidence reported
in previous published trials, we expected a 5% incidence of
periprocedural major bleeding, thus giving a sample size of
at least 150 patients (95% CI ± 1.5). The study protocol was
reviewed and approved by the Institutional Review Board.
Written formal consent was obtained from all patients
enrolled in the study.
Outcome Assessments
Outcome of our investigation was the observed incidence of
bleeding and thrombotic complications. We reported the inci-
dence of any arterial or venous thromboembolic events occur-
ring at any time during the study period (from VKA suspension
to 30 ± 2 days thereafter). Arterial thromboembolic events
were deﬁned as ischaemic stroke documented by computed
tomography (CT) scan or magnetic resonance imaging], tran-
sient ischaemic attacks (TIAs), peripheral arterial TE, or throm-
bosis of the prosthetic mechanical valves. Venous thromboem-
bolic events were deﬁned as acute symptomatic deep vein
thrombosis (DVT), documented by compression ultrasound, or
acute symptomatic pulmonary embolism (PE) documented by
CT scan, pulmonary angiogram, or ventilation/perfusion scan.
Arterial events that occurred in patients with no history of AF
(i.e., enrolled because of a history of DVT) and venous events
that occurred in patients with no history of DVT (i.e., enrolled
because of a history of AF) were recorded and considered to
be part of the primary efﬁcacy endpoint.
We reported the incidence of major bleeding while on
LMWH and during the follow-up period. Major haemorrhage
was deﬁned as overt bleeding leading to a 20 g/L drop in
hemoglobin (compared to preoperative levels), transfusion
of 2 U of packed red blood cells, any bleeding that was
intracranial, retroperitoneal, or intraocular, requiring surgical
intervention, or resulting in death. All suspected major
bleeds were adjudicated by the study steering committee.
The secondary safety outcome was the rate of minor bleed-
ing while on LMWH or within 24 h after VKA discontinua-
tion. All bleeding events not meeting the criteria for major
bleeding were classiﬁed as minor.
Results
The study included 209 cancer patients on long-term anti-
coagulation therapy over a period of 5 years (2005–2010),
investigated because of the need for invasive procedures,
surgery or due to chemotherapy-induced thrombocytopenia.
Among them, 44 were excluded (16 because of minor sur-
gery or simple dental procedure, 4 because of renal insufﬁ-
ciency, 3 because of a previous major bleeding episode, 2
because of persistent low-platelet counts not related to
chemotherapy, 14 because of severe associated pathologies,
and 5 because of body weight  40 kg or 100 kg). In total,
165 patients were included in the study, 9 of which did not
receive study medication. A total of 156 patients [88 (56.4%)
at low risk and 68 (43.5%) at high risk of thrombosis] were
enrolled. Eleven patients (7.0%) discontinued LMWH prema-
turely: eight for bleeding events, two for protocol violation
(patients belonging to the high-risk group received prophy-
lactic instead of subtherapeutic LMWH in the postprocedural
period), and one lost during follow-up. These subjects were
still considered part of the ITT population.
Baseline characteristics of the study population, as well as
VKA indications, are shown in Table I. Among the 156
patients, 54 (34.6%) underwent major surgery, 63 (40.4%),
nonmajor surgery, and 39 (25%), chemotherapy. Major sur-
gery included the following procedures: 5 (9.2%) orthopedic,
16 (29.6%) abdominal, 8 (14.8%) urologic, 5 (9.2%) thoracic/
lung, 8 (14.8%) gynaecologic, 11 (20.3%) mammary, and 3
(5.5%) neurosurgery. Nonmajor surgeries included 21
(33.3%) gastrointestinal endoscopies, 18 (28.5%) biopsies,
10 (15.8%) cutaneous surgeries, 11 (17.4%) urologic/gynae-
cologic (such as cystoscopies), and 3 (4.7%) arthroscopies.
The mean LMWH administration times (6.8 days) and the
mean time required to reach a therapeutic INR level (5.6
days) were not different among low or high-risk patients ei-
ther considering those underwent (major and nonmajor) sur-
gery or chemotherapy-induced thrombocytopenia. Most
patients undergoing nonmajor invasive procedures received
LMWH at home, while the majority of patients planning to
undergo major surgery or chemotherapy-induced thrombocy-
topenia received LMWH in the hospital.
Overall, thromboembolic events occurred in ﬁve patients
(3.2%, 95% CI: 1.41–7.27), four belonging to the high-risk
group (one during chemotherapy-induced thrombocytopenia)
and one from the low-risk group. Three events (one TIA and
two DVT) occurred in the AF-AT patient group, while two
events (isolated PE and DVT with PE) occurred in the VTE
patient group (Table II). All events occurred after surgery while
patients were on anticoagulants, none of which were fatal.
Overall, major bleeding occurred in ﬁve patients (3.2%, 95
CI: 1.41–7.27), all belonging to the high-risk group (three
during major surgery and two during chemotherapy; Table
III). No bleeding event was fatal, intracranial, retroperitoneal,
or intraocular. Four major bleeding events occurred during,
or a few days after, major surgery, while one occurred in a
patient undergoing chemotherapy. In patients who experi-
enced bleeding events, LMWH was not administered, and
VKA resumption was postponed until stable hemostasis was
reached as determined clinically and by laboratory values.
In the group of patients who experienced chemotherapy-
induced thrombocytopenia, the rate of thrombosis and major
TABLE II. Thromboembolic Events in the Low-Risk, High-Risk, and Total Patient Groups
Events, n (%) Low-risk group (68) High-risk group (88) Total (156)
P value among low
and high-risk groupa
TE total, n (%, 95% CI) 1 (1.4, 95% CI: 0.35–7.81) 4b (4.5, 95% CI: 1.84–11.10) 5 (3.2, 95% CI: 1.41–7.27 0.387
Arterial, n (%, 95% CI) 0 1 (1.1, 95% CI: 0.27–6.10) 1 (0.6, 95% CI: 0.15–3.49) 1.0




One event occurred in this group during chemotherapy-induced thrombocytopenia.
Abbreviations: TE, thromboembolism; AF-AT, atrial ﬁbrillation with previous stroke; VTE, venous thromboembolism; CI, conﬁdence interval.
TABLE III. Incidence of Major Bleeding Events in the Low and High-Risk
Groups Accordingly to Type of Procedure
Type of procedure (n)
Low-risk
group High-risk group
Major surgery (54) n (%, 95% CI) 0 3 (5.5, 95% CI: 2.0–15.1)
Non-major surgery (63) n (%, 95% CI) 0 0
Chemotherapy-induced
thrombocytopenia (49) n (%, 95% CI)
0 2 (4.1, 95% CI: 1.2–13.7)
CI, conﬁdence interval.
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bleeding was 2.0 (95% CI: 0.48–10.6) and 4.1% (95% CI:
1.2–13.7), respectively. The median nadir platelet count was
35.000 mmc3 (range, 9.000–94.000 mmc3); patients received
platelet transfusions (by apheresis or randomly assigned)
when platelets drop to 10.000 mmc3 or with a platelet count
of 10.000 – 50.000 mmc3 in case of bleeding.
Minor bleedings occurred in 4 of 68 patients (5.9%, 95%
CI: 2.39–14.2) in the low-risk group and 7/58 (12%, 95%
CI: 6.0–22.9) in the high-risk group. Eight events occurred
after VKA therapy was resumed. Three deaths occurred
during the 30 days of follow-up, but none was related to
major outcomes (recurrent thrombosis or major bleeding).
Discussion
The perioperative management of patients who require
the temporary interruption of VKA is a common and chal-
lenging clinical problem. Physicians must balance the risk
of thromboembolic events if VKA is discontinued with the
risk of bleeding from the procedure if warfarin is continued.
In a noncancer population, the 8th edition of American Col-
lege of Chest Physicians states that patients on long-term
VKA therapy at a high risk of thrombosis should receive
bridging anticoagulation with a therapeutic-dose of s.c.
LMWH or intravenous UFH during the temporary interrup-
tion of VKA therapy [1]. In patients at a moderate risk of
TE, even a low dose of LMWH is allowed, while in patients
at a low risk of TE, a low dose of LMWH is recommended.
However, no data are available for a cancer population, a
population at a high risk of thrombosis and bleeding.
For the ﬁrst time in patients with active cancer, we eval-
uated a standardized bridging anticoagulation regimen with
ﬁxed doses of LMWH. In our series of 156 patients requir-
ing the interruption of VKA because of invasive procedures,
or due to chemotherapy-induced thrombocytopenia, our
approach was associated with a relatively low risk of throm-
boembolic events (3.2%) and major haemorrhages (3.2%).
As expected, major bleeding occurred more frequently in
the group who underwent major surgery. After 30 days of
follow-up, no patient died due to bleeding or thrombosis.
These results are not different from those obtained in a
noncancer population, where, using adjusted instead of
ﬁxed doses of LMWH, the rate of recurrent thrombosis and
major bleeding ranged from 0.4 to 3.6% and from 1.2 to
20%, respectively [2–8]. As expected, we found a higher
rate of events than those obtained in the noncancer popula-
tion, using the same LMWH administration scheme. In this
latter population, the rate of recurrent thrombosis and major
bleeding was 1.8 and 2.1%, respectively [13]; however, a
direct comparison is not easy to perform.
This cohort has several features that support the validity
of the results. First, unlike most registries in which patient
treatment is left to the discretion of the treating physician
[14–16], patients received a standardized periprocedural
anticoagulation regimen. This approach has several advan-
tages. First, it simpliﬁes the management of patients either
pre- or postoperatively. Additionally, it is considered that the
surgeon often feels uncomfortable, at least in our experi-
ence, giving therapeutic doses of heparin on the day imme-
diately following surgery. This is particularly true in cases of
chemotherapy-induced thrombocytopenia where no data
are available concerning the platelet threshold considered
safe for heparin administration, timing, and dosage. Finally,
patients underwent a clinical follow-up during the preproce-
dural and postprocedural periods for up to 30 days, thus
allowing us to detect any clinically relevant event.
There are some limitations that should be addressed.
First, our study, similar to those in the noncancer population,
lacked a comparison group. Without an untreated control
group, we cannot determine whether such an approach
reduced the incidence of TE or increased the frequency of
bleeding. Only a randomized trial can address this clinical
issue, but at present, none has been published. Second, our
results come from a single-center investigation, and this may
compromise data generalization. We cannot exclude such a
hypothesis, but this appears unlikely, because the incidence
of major events was similar to those reported in the non-
cancer populations evaluated in multicenter studies [2–8].
Finally, we excluded patients weighing 40 kg or 100 kg,
which may reduce the generalization of our results; however,
in our opinion, such patients should require an individualized
protocol with bodyweight-adjusted doses of heparin.
In conclusion, the use of ﬁxed doses of LMWH as a bridg-
ing regimen in cancer patients on long-term VKA is feasible
and appears to be safe, because it is associated with a rela-
tively low risk of recurrent thrombosis and major bleeding.
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